General principles of pharmacotherapy for the patient with HIV infection

doi:10.1017/CBO9780511543586.004

3 - General principles of pharmacotherapy for the patient with HIV infection

Published online by Cambridge University Press: 06 August 2009

Sanjay M. Sharma M.D., M.B.A. ,

J. Stepen McDaniel M.D. and

Nancy L. Sheehan B.Pharm., M.Sc.

Edited by

Kenneth Citron ,

Marie Josée Brouillette and

Alexandra Beckett

Show author details

Sanjay M. Sharma M.D., M.B.A.: Affiliation:
Assistant Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA
J. Stepen McDaniel M.D.: Affiliation:
Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA
Nancy L. Sheehan B.Pharm., M.Sc.: Affiliation:
HIV Pharmacotherapy Specialist, McGill University Health Centre, Montréal, Canada
Marie Josée Brouillette: Affiliation:
McGill University, Montréal
Alexandra Beckett: Affiliation:
Harvard University, Massachusetts

Book contents

Get access

Summary

Introduction

Over the past several years, highly active antiretroviral therapy (HAART) has become the pharmacological mainstay in the ongoing management of HIV infection and AIDS. This treatment regimen comprises a combination of antiretroviral medications which fall into four major classes including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and entry inhibitors (Table 3.1). Each medication within its respective class acts to inhibit the replication process of HIV at a distinct point in its viral life cycle. When used in combination therapy, these medications form a highly effective and powerful tool in the treatment of HIV infection and AIDS.

However, as effective and beneficial as these combination antiretroviral treatments are, the ongoing management of HIV infection may be complicated by potential side effects and drug–drug interactions.

In addition to being concerned about the impact of antiretrovirals on psychotropic medications, the clinician has to ensure that the psychopharmacological agents do not compromise HIV treatment or lead to the development of resistant strains of the virus.

This chapter:

describes the various potential drug–drug interactions and neuropsychiatric side effects that may occur when psychotropic medications, narcotics, recreationally used/abused drugs, and alternative agents are utilized concomitantly with antiretroviral treatment
offers practical recommendations on choosing psychotropic medications for a variety of psychiatric illnesses while respecting issues of safety and not compromising HIV care.

Type: Chapter
Information: HIV and Psychiatry
Training and Resource Manual
, pp. 56 - 87

DOI: https://doi.org/10.1017/CBO9780511543586.004 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abrams, D., Leiser, R., Shade, S. et al. Short-term safety of cannabinoids in HIV patients [Abstract 744]. 8thConference on Retroviruses and Opportunistic Infections, Chicago, USA, February 4–8, 2001.

Altice, F. L., Friedland, G. H. and Cooney, E. L.Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS, 13 (1999): 957–62.Google Scholar

American Psychiatric Association. Practice Guideline for the Treatment of Patients with HIV/AIDS. Washington, DC: American Psychiatric Association, 2000a.

American Psychiatric Association. Treatment recommendations for patients with bipolar disorder. In Practice Guidelines for the Treatment of Psychiatric Disorders (compendium), pp. 555–6. Washington, DC: American Psychiatric Association, 2000b.

Antoniou, T. and Tseng, A. L.Interactions between recreational drugs and antiretroviral agents. Annals of Pharmacotherapy, 36 (2002): 1598–613.Google Scholar

Armstrong, S. C.The Cytochrome P450 system drug interaction principles for medical practice. Washington, DC: American Psychiatric Publishing, Inc., 2001.

Bertz, R. J. and Granneman, R.Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32 (1997): 210–58.Google Scholar

Bezchlibynk-Butler, K. Z., and Jeffries, J. J.Clinical Handbook of Psychotropic Drugs, eds. 7th edn. Seattle, WA: Hogrefe and Huber Publishers, 1997.

Boroujerdi, M., Pharmacokinetics: Principles and Applications. New York: McGraw-Hill Companies, 2002.

Bornheim, L. M., Lasker, J. M. and Raucy, J. L.Human hepatic microsomal metabolism of delta l-tetrahydrocannabinol. Drug Metabolism and Disposition, 20 (1992): 241–6.Google Scholar

Brosen, K. and Naranjo, C. A.Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. European Neuropsychopharmacology, 11 (2001): 275–83.Google Scholar

Calabrese, J. R., Shelton, M. D., Rapport, D. J.et al. Long-term treatment of bipolar disorder with lamotrigine. Journal of Clinical Psychiatry, 63(Suppl. 10) (2002):18–22.Google Scholar

Clarke, S., Mulcahy, F., Bergin, C.et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitors lopinavir–ritonavir. Clinical Infectious Diseases, 34 (2002): 1143–5.Google Scholar

Cozza, K. L., and Armstrong, S. C.The Cytochrome P450 System Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing, 2001.

Maat, M. M. R., Hoetelmans, R. M. W., Mathot, R. A. A.et al. Drug interaction between St. John's wort and nevirapine. AIDS, 15 (2001): 420–1.Google Scholar

DeSilva, K. E., LeFlore, D. B., Marston, B. J. and Rimland, D.Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS, 15 (2001): 1281–5.Google Scholar

Dresser, G. K., Spence, J. D. and Bailey, D. G.Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical Pharmacokinetics, 38 (2000): 41–57.Google Scholar

Eagling, V. A., Back, D. J. and Barry, M. G.Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology, 44 (1997): 190–4.Google Scholar

Fletcher, C. V.Enfuvirtide, a new drug for HIV infection. Lancet, 361 (2003): 1577–8.Google Scholar

Freeman, M. P., Freeman, S. A. and McElroy, S. L.The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. Journal of Affective Disorders, 68 (2002): 1–23.Google Scholar

Goldberg, J. and Irving, K.Treatment goals of bipolar disorder. Medscape Psychiatry and Mental Health 8 (2003): 1–3 (Available as a living document at www.medscape.com).Google Scholar

Gourevitch, M. N.Interactions between HIV-related medications and methadone: an overview. The Mount Sinai Journal of Medicine, 68 (2001): 227–8.Google Scholar

Gourevitch, M. N. and Friedland, G. H.Interactions between methadone and medications used to treat HIV infection: a review. The Mount Sinai Journal of Medicine, 67 (2000): 429–36.Google Scholar

Halman, M.Management of depression and related neuropsychiatric symptoms associated with HIV/AIDS and antiretroviral therapy. Canadian Journal of Infectious Diseases, 12 (Suppl. C) (2001): 9–19.Google Scholar

Harrington, R. D., Woodward, J. A., Hooton, T. M.et al. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Archives of Internal Medicine, 159 (1999): 2221–4.Google Scholar

Hendrix, C., Wakeford, J., Wire, M. B. et al. Pharmacokinetic and pharmacodynamic evaluation of methadone enantiomers following co-administration with amprenavir in opioid-dependent subjects [Abstract 1649]. 40thInterscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17–20, 2000.

Henry, J. A. and Hill, I. R.Fatal interaction between ritonavir and MDMA [research letter]. Lancet, 352 (1998): 1751–2.Google Scholar

Keck, P. E. and McElroy, S. L.Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. Journal of Clinical Psychiatry, 63(Suppl. 4) (2002): 3–11.Google Scholar

Keck, P. E.Perlis, R. H., Otto, M. W.et al. The expert consensus guideline series: treatment of bipolar disorder 2004. Postgraduate Medicine (2004): 1–47.Google Scholar

Kreth, K., Kovar, K., Schwab, M. and Zanfar, U. M.Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related drugs. Biochemical Pharmacology, 15 (2000): 1563–71.Google Scholar

Koller, E. A. and Doraiswamy, P. M.Olanzapine-associated diabetes mellitus. Pharmacotherapy, 22 (2002): 841–52.Google Scholar

Kosel, B., Aweeka, F., Benowitz, N. et al. The pharmacokinetic effects of marijuana (THC) on nelfinavir and indinavir [Abstract 747]. 8thConference on Retroviruses and Opportunistic Infections, Chicago, USA, February 4–8, 2001.

Krishnan, R. R., Steffens, D. C. and Doraiswamy, P. M.Psychotropic Drug Interactions. New York: MBL Communications, Inc, (1996).

Ladona, M. G., Gonzalez, M. L., Rane, A.et al. Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Science, 68 (2000): 431–3.Google Scholar

Laurenzana, E. M. and Owens, S. M.Metabolism of phencyclidine by human liver microsomes. Drug Metabolism and Disposition, 25 (1997): 557–63.Google Scholar

Lin, L. Y., Di Stefano, E. W., Schmitz, D. A.et al. (1997). Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metabolism and Disposition, 25 (1997): 1059–64.Google Scholar

Lippman, S., Mazour, I. and Shahab, H.Insomnia: therapeutic approach. Southern Medical Journal, 94 (2001): 866–73.Google Scholar

Maggi, J. D. and Halman, M. H.The effect of divalproex sodium on viral load: a retrospective review of HIV-1-positive patients with manic syndromes. Canadian Journal of Psychiatry, 46(4) (2001): 359–62.Google Scholar

Marzolini, C., Telenti, A., Decosterd, L. A.et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15 (2001): 71–5.Google Scholar

McDowell, J. A., Chittick, G. E., Pilati-Stevens, C.et al. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrobial Agents and Chemotherapy, 44 (2000): 1686–90.Google Scholar

Moller, H. J. and Nasrallah, H. A.Treatment of bipolar disorder. Journal of Clinical Psychiatry, 64 (Suppl. 6) (2003): 9–17.Google Scholar

Montplaisir, J., Hawa, R., Moller, H.et al. Zoplicone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Human Psychopharmacology: Clinical and Experimental, 18 (2003): 29–38.Google Scholar

O'Mara, E. M., Mummaneni, V., Burchell, B. et al. Relationship between uridine diphosphate-glucuronosyl transferase 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir [Abstract 1645]. 40thInterscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17–20, 2000.

O'Mara, E., Mummaneni, V., Randall, D. et al. BMS-232632: A summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [Abstract 504]. 7thConference on Retroviruses and Opportunistic Infections, San Francisco, USA, January 3–February 2, 2000.

Organon Canada Ltd., Remeron (mirtazapine) product monograph. Scarborough, ON, 2001.

Osborne, R., Joel, S., Trew, D. and Slevin, M.Analgesic activity of morphine-6-glucuronide (letter). Lancet, 1 (1988): 828.Google Scholar

Pande, A. C., Crockatt, J. G., Janney, C. A.et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy [abstract]. Bipolar Disorders, 2 (2000): 249–55.Google Scholar

Park-Wyllie, L. Y. and Antoniou, T.Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series [letter]. AIDS, 17 (2003): 638–40.Google Scholar

Paterson, D. L., Swindells, S., Mohr, J.et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133 (2000): 21–30.Google Scholar

Penzak, S. R., Hon, Y. Y., Lawhorn, W. D.et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. Journal of Clinical Psychopharmacology, 22(2002): 366–70.Google Scholar

Physicians' Desk Reference, 57th edn. Montvale, NJ: Medical Economics, (2003).

Piscitelli, S. C., Burstein, A. H., Chaitt, D.et al. Indinavir concentrations and St. John's Wort [research letter]. Lancet, 355 (2000a): 547–8.Google Scholar

Piscitelli, S., Rock-Kress, D., Bertz, R., Pau, A. and Davey, R.The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacology, 20 (2000b): 549–53.Google Scholar

Piscitelli, S., Formentin, E., Burstein, A. H.et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy, 22 (2002a): 551–6.Google Scholar

Piscitelli, S. C., Burstein, A. H., Welden, N.et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clinical Infectious Diseases, 34 (2002b): 234–8.Google Scholar

Prior, T. I. and Baker, G. B.Interactions between cytochrome P450 system and the second-generation antipsychotics. Journal of Psychiatry and Neuroscience, 28 (2003): 99–112.Google Scholar

Rainey, P. M., Friedland, G., McCance-Katz, E. F.et al. Interaction of methadone with didanosine and stavudine. Journal of Acquired Immune Deficiency Syndrome, 24 (2000): 241–8.Google Scholar

Robertson, P. and Hellriegel, E. T.Clinical pharmacokinetic profile of modafinil. Clinical Pharmacokinetics, 42 (2003): 123–37.Google Scholar

Rubinstein, M. L. and Selwyn, P. A.High prevalence of insomnia in an outpatient population with HIV infection [abstract]. Journal of Acquired Immune Deficiency Syndromes, 19 (1998): 260–5.Google Scholar

Schwartz, E. L., Brechbuhl, A. B., Kahl, P.et al. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. Journal of Acquired Immune Deficiency Syndrome, 5 (1992): 619–26.Google Scholar

Tanquary, J.Lithium neurotoxicity at therapeutic levels in an AIDS patient. Journal of Nervous and Mental Disorders, 181(8)(1993): 518–19.Google Scholar

Thiemann, L. and Lalazeri, J.Double Jeopardy: The HIV/HCV Co-Infection Handbook. New York: Community Prescription Service, 1999.

Tseng, A. and Foisy, M.Significant interactions with new antiretrovirals and psychotropic drugs. Annals of Pharmacotherapy, 33 (1999): 461–72.Google Scholar

Tseng, A., Foisy, M. and Fletcher, D.2001 Handbook of HIV Drug Therapy. Toronto, 2002. (www.tthhivclinic.com/pdf/regimens01.pdf)

Moltke, L. L., Greenblatt, D. J., Grassi, J. M.et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. Journal of Clinical Pharmacology, 38 (1998): 106–11.Google Scholar

Watanabe, K., Matsunaga, T., Yamamoto, I.et al. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biological and Pharmaceutical Bulletin, 18 (1995): 1138–41.Google Scholar

Yanagihara, Y., Kariya, S., Ohtani, M.et al. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metabolism and Disposition, 29 (2001): 887–90.Google Scholar

Book contents

3 - General principles of pharmacotherapy for the patient with HIV infection

Summary

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive